Phreesia, Inc. (0A23.L)
USD 28.5
(-1.96%)
USD 28.5
(-1.96%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -102.94 Million USD | 29.24% |
| 2023 | -145.48 Million USD | -58.35% |
| 2022 | -92.29 Million USD | -878.34% |
| 2021 | -7.61 Million USD | -605.07% |
| 2020 | -3.72 Million USD | -53.51% |
| 2019 | 2.1 Million USD | 196.36% |
| 2018 | -4.91 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -30.91 Million USD | 3.41% |
| 2024 FY | - USD | 32.01% |
| 2024 Q2 | -30.17 Million USD | 2.86% |
| 2024 Q3 | -24.58 Million USD | 18.14% |
| 2024 Q4 | -21.13 Million USD | 8.58% |
| 2023 Q2 | -40.51 Million USD | 9.38% |
| 2023 FY | - USD | -58.35% |
| 2023 Q4 | -32.89 Million USD | 0.72% |
| 2023 Q3 | -33.12 Million USD | 18.23% |
| 2023 Q1 | -44.71 Million USD | -9.65% |
| 2022 Q1 | -5.7 Million USD | -41.6% |
| 2022 Q2 | -18.52 Million USD | -224.75% |
| 2022 Q3 | -30.5 Million USD | -64.67% |
| 2022 Q4 | -40.77 Million USD | -33.65% |
| 2022 FY | - USD | -878.34% |
| 2021 Q4 | -4.02 Million USD | -89.96% |
| 2021 Q3 | -2.12 Million USD | 6.48% |
| 2021 Q2 | -2.26 Million USD | -68.62% |
| 2021 FY | - USD | -605.07% |
| 2021 Q1 | -1.34 Million USD | -32.64% |
| 2020 Q1 | -457.32 Thousand USD | -206.42% |
| 2020 FY | - USD | -53.51% |
| 2020 Q3 | 1.24 Million USD | -42.24% |
| 2020 Q4 | -1.01 Million USD | -181.32% |
| 2020 Q2 | 2.15 Million USD | 572.06% |
| 2019 Q2 | 2.08 Million USD | 95.61% |
| 2019 Q1 | 1.06 Million USD | 0.0% |
| 2019 Q3 | 578 Thousand USD | -72.27% |
| 2019 FY | - USD | 196.36% |
| 2019 Q4 | 429.72 Thousand USD | -25.65% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Accuray Incorporated | 9 Million USD | 1242.691% |
| Align Technology, Inc. | 799.03 Million USD | 112.884% |
| Elevance Health Inc. | 10.49 Billion USD | 100.981% |
| AxoGen, Inc. | -13.32 Million USD | -672.396% |
| Boston Scientific Corporation | 3.61 Billion USD | 102.849% |
| CVS Health Corporation | 18.17 Billion USD | 100.566% |
| Cardinal Health, Inc. | 1.97 Billion USD | 105.204% |
| Centene Corporation | -463 Million USD | 77.766% |
| DaVita Inc. | 2.34 Billion USD | 104.387% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 100.809% |
| Hologic, Inc. | 1.29 Billion USD | 107.942% |
| Humana Inc. | -561 Million USD | 81.65% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 108.454% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | 107.629% |
| Masimo Corporation | 236.7 Million USD | 143.492% |
| McKesson Corporation | 4.66 Billion USD | 102.206% |
| Patterson Companies, Inc. | 374.75 Million USD | 127.47% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | 105.944% |
| ResMed Inc. | 1.6 Billion USD | 106.433% |
| Henry Schein, Inc. | 943 Million USD | 110.917% |
| Teladoc Health, Inc. | 153.99 Million USD | 166.849% |
| Universal Health Services, Inc. | 1.74 Billion USD | 105.905% |
| Veeva Systems Inc. | 429.33 Million USD | 123.978% |
| Baxter International Inc. | 2.77 Billion USD | 103.708% |
| Becton, Dickinson and Company | 4.27 Billion USD | 102.408% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 104.3% |
| Danaher Corporation | 7.49 Billion USD | 101.373% |
| Stryker Corporation | 5.16 Billion USD | 101.995% |
| Medtronic plc | 9.05 Billion USD | 101.137% |